1. Home
  2. SCLX vs NVNI Comparison

SCLX vs NVNI Comparison

Compare SCLX & NVNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • NVNI
  • Stock Information
  • Founded
  • SCLX 2011
  • NVNI 2019
  • Country
  • SCLX United States
  • NVNI Brazil
  • Employees
  • SCLX N/A
  • NVNI N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • NVNI
  • Sector
  • SCLX Health Care
  • NVNI
  • Exchange
  • SCLX Nasdaq
  • NVNI Nasdaq
  • Market Cap
  • SCLX 33.9M
  • NVNI 31.5M
  • IPO Year
  • SCLX N/A
  • NVNI N/A
  • Fundamental
  • Price
  • SCLX $6.38
  • NVNI $0.34
  • Analyst Decision
  • SCLX Strong Buy
  • NVNI
  • Analyst Count
  • SCLX 3
  • NVNI 0
  • Target Price
  • SCLX $367.50
  • NVNI N/A
  • AVG Volume (30 Days)
  • SCLX 96.4K
  • NVNI 1.4M
  • Earning Date
  • SCLX 08-12-2025
  • NVNI 08-07-2025
  • Dividend Yield
  • SCLX N/A
  • NVNI N/A
  • EPS Growth
  • SCLX N/A
  • NVNI N/A
  • EPS
  • SCLX N/A
  • NVNI N/A
  • Revenue
  • SCLX $50,710,000.00
  • NVNI $31,250,627.00
  • Revenue This Year
  • SCLX $107.00
  • NVNI $12.05
  • Revenue Next Year
  • SCLX $82.52
  • NVNI $15.02
  • P/E Ratio
  • SCLX N/A
  • NVNI N/A
  • Revenue Growth
  • SCLX 7.79
  • NVNI 1491.58
  • 52 Week Low
  • SCLX $3.60
  • NVNI $0.14
  • 52 Week High
  • SCLX $73.50
  • NVNI $12.19
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 60.64
  • NVNI 51.35
  • Support Level
  • SCLX $6.00
  • NVNI $0.28
  • Resistance Level
  • SCLX $6.76
  • NVNI $0.38
  • Average True Range (ATR)
  • SCLX 0.42
  • NVNI 0.03
  • MACD
  • SCLX 0.11
  • NVNI 0.01
  • Stochastic Oscillator
  • SCLX 82.06
  • NVNI 64.11

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

Share on Social Networks: